JAK2 V617F mutation prevalence in myeloproliferative neoplasms in Pernambuco, Brazil.

BACKGROUND: The JAK2 V617F mutation is associated with three myeloproliferative neoplasms (MPNs): polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). It generates an unregulated clonal hematopoietic progenitor and leads to abnormal increased proliferation of one or more myeloid lineages. Subjects bearing this mutation may present more frequently with complications such as thrombosis and bleeding, and no specific treatment has yet been developed for BCR-ABL-negative JAK2 V617F-negative MPNs. AIMS: To determine the prevalence of JAK2 V617F in MPNs in Pernambuco, Brazil, and to compare it with previous studies. MATERIAL AND METHODS: 144 blood samples were collected at the Hospital of Hematology of the HEMOPE Foundation and were genotyped by polymerase chain reaction-restriction fragment length polymorphism with BsaXI enzymatic digestion. RESULTS AND DISCUSSION: 88% (46/52) of the patients with PV, 47% (39/81) with ET, and 77% (8/11) with PMF were positive for JAK2 V617F, while more than 35% of the individuals were JAK2 V617F-negative, confirming a high prevalence of this abnormality in MPNs, more frequently with a low mutated allele burden, similar to what has been reported in other Western countries, despite differences among methods used to detect this mutation. Screening for JAK2 V617F may allow specific management of these diseases with JAK2 inhibitors in the future and highlights the need for further studies on the pathogenesis of BCR-ABL-negative JAK2 V617F-negative MPNs.

Flow cytometry protocol to evaluate ionizing radiation effects on P-glycoprotein activity

The aim of this work was to establish a protocol to evaluate ionizing radiation effects on P-glycoprotein (P-gp) activity. For this, human peripheral blood samples were irradiated in vitro with different doses and P-gp activity was analyzed for CD4 and CD8 T lymphocytes through rhodamine123-efflux assay by flow cytometry. By simultaneous employment of percentage and mean fluorescence index parameters, subject-by-subject analysis pointed out changes in P-gp activity for some individuals and irradiated samples. Based on this work, the proposed protocol was considered adequate for evaluating P-gp activity on cells after radioactive stress. Besides, this research suggests that P-gp activity could be an important factor to define patient-specific protocols in combined chemo-and radiotherapy, particularly when radiation exposure precedes chemical treatment.

O objetivo deste trabalho foi estabelecer um protocolo para avaliar o efeito da radiação ionizante na atividade da glicoproteína-P (gp-P). Para isto, amostras de sangue periférico humano foram irradiadas in vitro com diferentes doses, e a atividade da gp-P foi analisada para os linfócitos T CD4 e CD8 através do ensaio do efluxo da rodamina123 por citometria de fluxo. Por emprego simultâneo dos parâmetros de porcentagem e índice médio de fluorescência, a análise indivíduo por indivíduo apontou mudanças na atividade da gp-P para alguns indivíduos e amostras irradiadas. Com base neste trabalho, o protocolo proposto foi considerado adequado para avaliar a atividade da gp-P em células após estresse radioativo. Além disso, esta pesquisa sugere que a atividade da gp-P poderia ser um importante fator para definir protocolos paciente-específicos envolvendo quimio e radioterapia, particularmente quando a exposição à radiação precede o tratamento químico.